Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $20.40

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been given a consensus rating of “Buy” by the six ratings firms that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $20.40.

Several brokerages have issued reports on ARTV. Wedbush reissued an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald dropped their target price on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 25th.

Artiva Biotherapeutics Trading Up 4.5 %

NASDAQ ARTV opened at $2.20 on Friday. Artiva Biotherapeutics has a 12 month low of $1.78 and a 12 month high of $17.31. The company’s fifty day moving average price is $3.24 and its two-hundred day moving average price is $6.93.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.15). Analysts predict that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new position in shares of Artiva Biotherapeutics during the 4th quarter worth about $52,000. Wells Fargo & Company MN grew its stake in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after purchasing an additional 3,361 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock worth $100,000 after buying an additional 7,151 shares during the period. JPMorgan Chase & Co. acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $166,000. Finally, Deutsche Bank AG acquired a new position in Artiva Biotherapeutics during the fourth quarter worth $216,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.